Review
Impact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis

https://doi.org/10.1016/j.dsx.2021.102308Get rights and content

Highlights

  • Diabetes mellitus, hypertension and cardiovascular disease increased the risk of critical or fatal COVID-19.

  • Most prevalent comorbidity amongst COVID-19 patients was hypertension.

  • Strongest risk factor for a poor outcome was underlying cardiovascular disease.

Abstract

Background and aims

This meta-analysis aims to highlight the impact of cardio-metabolic comorbidities on COVID-19 severity and mortality.

Methods

A thorough search on major online databases was done for studies describing the clinical outcomes of COVID-19 patients. We used random-effects model to compute pooled estimates for critical or fatal disease.

Results

A total of 20,475 patients from 33 eligible studies were included. Maximum risk of development of critical or fatal COVID-19 disease was seen in patients with underlying cardiovascular disease [OR: 3.44, 95% CI: 2.65–4.48] followed by chronic lung disease, hypertension and diabetes mellitus. Of the total cases, 64% had one of the four comorbidities with the most prevalent being hypertension with a pooled prevalence of 27%.

Conclusions

Presence of comorbidities like cardiovascular disease, chronic lung disease, hypertension and diabetes mellitus led to a higher risk of development of critical or fatal COVID-19 disease, with maximum risk seen with underlying cardiovascular disease.

Keywords

COVID-19
SARS-CoV-2
Hypertension
Diabetes mellitus
Cardiovascular disease
Meta-analysis
Systematic review

Cited by (0)

View Abstract